REGENXBIO Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

RGNX$7.69-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share data)

	Years Ended December 31,
	2023	2022	2021
Revenues
License and royalty revenue	$90,242	$112,724	$470,347
Total revenues	90,242	112,724	470,347
Operating Expenses
Cost of revenues	37,213	54,545	51,833
Research and development	232,266	242,453	181,437
General and administrative	88,494	85,281	79,333
Credit losses (recoveries)	—	—	(2,569)
Other operating expenses (income)	397	(6,679)	333
Total operating expenses	358,370	375,600	310,367
Income (loss) from operations	(268,128)	(262,876)	159,980
Other Income (Expense)
Interest income from licensing	25	342	719
Investment income	11,319	5,383	6,825
Interest expense	(6,862)	(23,254)	(26,277)
Total other income (expense)	4,482	(17,529)	(18,733)
Income (loss) before income taxes	(263,646)	(280,405)	141,247
Income Tax Benefit (Expense)	152	84	(13,407)
Net income (loss)	$(263,494)	$(280,321)	$127,840
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net	10,972	(12,832)	(2,209)
Total other comprehensive income (loss)	10,972	(12,832)	(2,209)
Comprehensive income (loss)	$(252,522)	$(293,153)	$125,631
Net income (loss) per share:
Basic	$(6.02)	$(6.50)	$3.01
Diluted	$(6.02)	$(6.50)	$2.91
Weighted-average common shares outstanding:
Basic	43,734	43,152	42,438
Diluted	43,734	43,152	43,913

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.